Oryon Cell Therapies

Oryon Cell Therapies (Oryon) - a clinical-stage biotechnology company focused on developing autologous neuron replacement medicines for Parkinson’s disease and other neurodegenerative disorders, today announced new clinical and neuroimaging data from an ongoing Phase 1b/2a study evaluating its autologous dopaminergic neuron replacement therapy for Parkinson’s disease.

The study is being conducted in collaboration with expertise across Mass General Brigham led by the Neuro. regeneration Institute at McLean Hospital.

Study participants received unilateral neuronal implants. The data show improvements in motor function, together with neuroimaging consistent with restoration of dopaminergic signaling in the . . .